NASDAQ: DSGNDesign Therapeutics Inc Stock
$3.50+0.12 (+3.55%)
Updated Apr 17, 2025
DSGN Price
$3.50
Fair Value Price
$0.37
Market Cap
$198.67M
52 Week Low
$2.60
52 Week High
$7.77
P/E
-3.98x
P/B
0.82x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$49.59M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.04
Operating Cash Flow
-$43M
Beta
1.42
Next Earnings
May 6, 2025
Ex-Dividend
N/A
Next Dividend
N/A
DSGN Overview
Design Therapeutics, Inc. is a preclinical-stage biopharmaceutical company developing treatments for genetic diseases caused by nucleotide repeat expansions. Design Therapeutics uses its proprietary GeneTAC platform to design its candidates. Design Therapeutics was incorporated in 2017 and is headquartered in Carlsbad, CA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine DSGN's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
DSGN
Ranked#219 of 463
Ranked#219 of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.61 | A | |
| $7.75 | A | |
| $16.85 | A |
Be the first to know about important DSGN news, forecast changes, insider trades & much more!
DSGN News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how DSGN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
DSGN ($3.50) is overvalued by 841.82% relative to our estimate of its Fair Value price of $0.37 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
DSGN ($3.50) is not significantly undervalued (841.82%) relative to our estimate of its Fair Value price of $0.37 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
DSGN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more DSGN due diligence checks available for Premium users.
Valuation
DSGN fair value
Fair Value of DSGN stock based on Discounted Cash Flow (DCF)
Price
$3.50
Fair Value
$0.37
Overvalued by
841.82%
DSGN ($3.50) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
DSGN ($3.50) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
DSGN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
DSGN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-3.98x
Industry
-177.72x
Market
27.98x
DSGN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.82x
Industry
4.05x
DSGN is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
DSGN's financial health
Profit margin
Revenue
$0.0
Net Income
-$13.7M
Profit Margin
0%
DSGN's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$252.1M
Liabilities
$10.0M
Debt to equity
0.04
DSGN's short-term assets ($248.04M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
DSGN's short-term assets ($248.04M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
DSGN's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
DSGN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$9.9M
Investing
$1.8M
Financing
$263.0k
DSGN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
DSGN vs Biotech Stocks
Design Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.